D.E. Shaw & Co
CRL icon

D.E. Shaw & Co’s Charles River Laboratories CRL Stock Holding History

D.E. Shaw & Co’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,500
Closed -$5.46M – 5592
2021
Q4 		$5.46M Buy
14,500
+8,000
+123% +$3.11M ﹤0.01% 2274
2021
Q3 		$2.68M Buy
+6,500
New +$2.7M ﹤0.01% 2735

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

D.E. Shaw & Co's CRL Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Charles River Laboratories (CRL) stake by 84% in Q2 2026, selling an estimated $28.8M and leaving 31,587 shares worth $7.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2121.

D.E. Shaw & Co first reported a position in CRL in Q2 2013 and has held it in 47 quarters since. The position peaked at $150M in Q3 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • D.E. Shaw & Co held 31,587 shares of Charles River Laboratories worth $7.16M as of Q2 2026.
  • D.E. Shaw & Co sold 161,896 Charles River Laboratories shares in Q2 2026, an estimated $28.8M.
  • Charles River Laboratories made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2121 holding.
  • D.E. Shaw & Co first reported a position in Charles River Laboratories in Q2 2013 and has held it in 47 quarters since.
  • D.E. Shaw & Co's Charles River Laboratories position peaked at $150M in Q3 2025.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.